These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

323 related articles for article (PubMed ID: 32365228)

  • 61. Use of all-trans retinoic acid plus arsenic trioxide as an alternative to chemotherapy in untreated acute promyelocytic leukemia.
    Estey E; Garcia-Manero G; Ferrajoli A; Faderl S; Verstovsek S; Jones D; Kantarjian H
    Blood; 2006 May; 107(9):3469-73. PubMed ID: 16373661
    [TBL] [Abstract][Full Text] [Related]  

  • 62. Effect of all-trans-retinoic acid alone or in combination with chemotherapy in newly diagnosed acute promyelocytic leukaemia.
    Colović MD; Janković GM; Elezović I; Vidović A; Bila JS; Novak A; Babić D
    Med Oncol; 1997 Jun; 14(2):65-72. PubMed ID: 9330265
    [TBL] [Abstract][Full Text] [Related]  

  • 63. Therapy of molecular relapse in acute promyelocytic leukemia.
    Lo Coco F; Diverio D; Avvisati G; Petti MC; Meloni G; Pogliani EM; Biondi A; Rossi G; Carlo-Stella C; Selleri C; Martino B; Specchia G; Mandelli F
    Blood; 1999 Oct; 94(7):2225-9. PubMed ID: 10498592
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Oral arsenic and retinoic acid for high-risk acute promyelocytic leukemia.
    Ma YF; Lu Y; Wu Q; Lou YJ; Yang M; Xu JY; Sun CH; Mao LP; Xu GX; Li L; Huang J; Wang HY; Lou LJ; Meng HT; Qian JJ; Yu WJ; Wei JY; Li ZY; Zhu XL; Yan XY; Chen SN; Jin J; Zhu HH
    J Hematol Oncol; 2022 Oct; 15(1):148. PubMed ID: 36258250
    [TBL] [Abstract][Full Text] [Related]  

  • 65. Upfront maintenance therapy with arsenic trioxide in acute promyelocytic leukemia provides no benefit for non-t(15;17) subtype.
    Chiang YH; Chang YF; Hsieh RK; Lin J; Chen CG; Lim KH; Lin HC; Chang MC
    Asia Pac J Clin Oncol; 2012 Dec; 8(4):330-6. PubMed ID: 22897350
    [TBL] [Abstract][Full Text] [Related]  

  • 66. A randomized comparison of all transretinoic acid (ATRA) followed by chemotherapy and ATRA plus chemotherapy and the role of maintenance therapy in newly diagnosed acute promyelocytic leukemia. The European APL Group.
    Fenaux P; Chastang C; Chevret S; Sanz M; Dombret H; Archimbaud E; Fey M; Rayon C; Huguet F; Sotto JJ; Gardin C; Makhoul PC; Travade P; Solary E; Fegueux N; Bordessoule D; Miguel JS; Link H; Desablens B; Stamatoullas A; Deconinck E; Maloisel F; Castaigne S; Preudhomme C; Degos L
    Blood; 1999 Aug; 94(4):1192-200. PubMed ID: 10438706
    [TBL] [Abstract][Full Text] [Related]  

  • 67. All-transretinoic acid and chemotherapy in the treatment of acute promyelocytic leukemia.
    Al Bahar S; Pandita R; Bavishi K; Kreze O
    Indian J Cancer; 2004; 41(3):125-8. PubMed ID: 15472411
    [TBL] [Abstract][Full Text] [Related]  

  • 68. Combined arsenic trioxide and all-trans retinoic acid treatment for acute promyelocytic leukaemia recurring from previous relapses successfully treated using arsenic trioxide.
    Au WY; Chim CS; Lie AK; Liang R; Kwong YL
    Br J Haematol; 2002 Apr; 117(1):130-2. PubMed ID: 11918543
    [TBL] [Abstract][Full Text] [Related]  

  • 69. [Effect of all-trans retinoic acid on the newly diagnosed acute promyelocytic leukaemia: our experience].
    Rolovitsh Z; Cholovitsh M; Elezovitsh I; Vidovitsh A; Radoshevitsh-Radojkovitsh N; Boshkovitsh D; Novak A; Basara N
    Srp Arh Celok Lek; 1995; 123(11-12):279-85. PubMed ID: 16296239
    [TBL] [Abstract][Full Text] [Related]  

  • 70. Comparison of clinical outcomes of patients with relapsed acute promyelocytic leukemia induced with arsenic trioxide and consolidated with either an autologous stem cell transplant or an arsenic trioxide-based regimen.
    Thirugnanam R; George B; Chendamarai E; Lakshmi KM; Balasubramanian P; Viswabandya A; Srivastava A; Chandy M; Mathews V
    Biol Blood Marrow Transplant; 2009 Nov; 15(11):1479-84. PubMed ID: 19822309
    [TBL] [Abstract][Full Text] [Related]  

  • 71. Outcomes and prognostic factors of first relapsed acute promyelocytic leukemia patients undergoing salvage therapy with intravenous arsenic trioxide and chemotherapy.
    Lou Y; Suo S; Tong Y; Tong H; Qian W; Meng H; Mai W; Huang J; Yu W; Jin J
    Ann Hematol; 2014 Jun; 93(6):941-8. PubMed ID: 24408159
    [TBL] [Abstract][Full Text] [Related]  

  • 72. Improved Outcomes With Retinoic Acid and Arsenic Trioxide Compared With Retinoic Acid and Chemotherapy in Non-High-Risk Acute Promyelocytic Leukemia: Final Results of the Randomized Italian-German APL0406 Trial.
    Platzbecker U; Avvisati G; Cicconi L; Thiede C; Paoloni F; Vignetti M; Ferrara F; Divona M; Albano F; Efficace F; Fazi P; Sborgia M; Di Bona E; Breccia M; Borlenghi E; Cairoli R; Rambaldi A; Melillo L; La Nasa G; Fiedler W; Brossart P; Hertenstein B; Salih HR; Wattad M; Lübbert M; Brandts CH; Hänel M; Röllig C; Schmitz N; Link H; Frairia C; Pogliani EM; Fozza C; D'Arco AM; Di Renzo N; Cortelezzi A; Fabbiano F; Döhner K; Ganser A; Döhner H; Amadori S; Mandelli F; Ehninger G; Schlenk RF; Lo-Coco F
    J Clin Oncol; 2017 Feb; 35(6):605-612. PubMed ID: 27400939
    [TBL] [Abstract][Full Text] [Related]  

  • 73. Acute promyelocytic leukemia: all-trans retinoic acid (ATRA) along with chemotherapy is superior to ATRA alone.
    Advani SH; Nair R; Bapna A; Gladstone B; Kadam P; Saikia TK; Parekh PM; Gopal R; Nair CN
    Am J Hematol; 1999 Feb; 60(2):87-93. PubMed ID: 9929098
    [TBL] [Abstract][Full Text] [Related]  

  • 74. Results of the APML3 trial incorporating all-trans-retinoic acid and idarubicin in both induction and consolidation as initial therapy for patients with acute promyelocytic leukemia.
    Iland H; Bradstock K; Seymour J; Hertzberg M; Grigg A; Taylor K; Catalano J; Cannell P; Horvath N; Deveridge S; Browett P; Brighton T; Chong L; Springall F; Ayling J; Catalano A; Supple S; Collins M; Di Iulio J; Reynolds J;
    Haematologica; 2012 Feb; 97(2):227-34. PubMed ID: 21993673
    [TBL] [Abstract][Full Text] [Related]  

  • 75. AIDA (all-trans retinoic acid + idarubicin) in newly diagnosed acute promyelocytic leukemia: a Gruppo Italiano Malattie Ematologiche Maligne dell'Adulto (GIMEMA) pilot study.
    Avvisati G; Lo Coco F; Diverio D; Falda M; Ferrara F; Lazzarino M; Russo D; Petti MC; Mandelli F
    Blood; 1996 Aug; 88(4):1390-8. PubMed ID: 8695858
    [TBL] [Abstract][Full Text] [Related]  

  • 76. Treatment of relapsed acute promyelocytic leukemia by arsenic trioxide in Iran.
    Alimoghaddam K; Ghavamzadeh A; Jahani M; Mousavi A; Iravani M; Rostami S; Ghaffari H; Hosseini R; Jalili M
    Arch Iran Med; 2011 May; 14(3):167-9. PubMed ID: 21529103
    [TBL] [Abstract][Full Text] [Related]  

  • 77. [Effectiveness of trans-retinoic acid in the treatment of acute promyelocytic leukemia: initial results of a multicenter study].
    Parovichnikova EN; Savchenko VG; Kliasova GA; Isaev VG; Demidova IA; Ol'shanskaia IuV; Tiurina NG; Tikhonova LIu; Galstian GM; Pivnik AV
    Ter Arkh; 1999; 71(7):20-4. PubMed ID: 10481862
    [TBL] [Abstract][Full Text] [Related]  

  • 78. [Long-term follow-up of treatment outcome and prognosis on 46 children with acute promyelocytic leukemia].
    Xu XJ; Shi SW; Tang YM; Song H; Yang SL; Wei J; Xu WQ; Pan BH; Chen YH; Zhao FY; Shen HQ; Qian BQ; Zhang LY; Ning BT
    Zhongguo Dang Dai Er Ke Za Zhi; 2007 Feb; 9(1):28-33. PubMed ID: 17306073
    [TBL] [Abstract][Full Text] [Related]  

  • 79. A phase II study evaluating the role of bortezomib in the management of relapsed acute promyelocytic leukemia treated upfront with arsenic trioxide.
    Kulkarni U; Ganesan S; Alex AA; Palani H; David S; Balasundaram N; Venkatraman A; Thenmozhi M; Jeyaseelan L; Korula A; Devasia A; Abraham A; Janet NB; Balasubramanian P; George B; Mathews V
    Cancer Med; 2020 Apr; 9(8):2603-2610. PubMed ID: 32059085
    [TBL] [Abstract][Full Text] [Related]  

  • 80. High efficacy of arsenic trioxide plus all-trans retinoic acid based induction and maintenance therapy in newly diagnosed acute promyelocytic leukemia.
    Lou Y; Qian W; Meng H; Mai W; Tong H; Tong Y; Huang J; Jin J
    Leuk Res; 2013 Jan; 37(1):37-42. PubMed ID: 23017225
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 17.